CD34-positive circulating cells quantification during follow-up in myeloproliferative neoplasms

Area of Science:

• Hematology
• Oncology
• Cell Biology

Background:

• Polycythemia vera (PV) and Essential thrombocythemia (ET) are myeloproliferative neoplasms (MPNs).
• MPNs can progress to myelofibrosis (MF), a complication linked to increased mortality.
• Circulating CD34-positive cells can help differentiate primary MF from other MPNs.

Purpose of the Study:

• To evaluate the utility of serial CD34-positive cell quantifications in monitoring MPN patients.
• To assess the diagnostic and prognostic value of CD34-positive cell counts in MPN progression to myelofibrosis.

Main Methods:

• Retrospective analysis of 180 MPN patients (ET, PV, MF) with at least two CD34-positive cell measurements.
• Evaluation of CD34-positive cell counts for diagnosing post-ET/PV myelofibrosis.
• Analysis of CD34-positive cell levels in relation to treatment response and overall survival in myelofibrosis.

Main Results:

• CD34-positive cell count demonstrated high accuracy (AUC 0.901) for diagnosing post-ET/PV myelofibrosis at a threshold of 15 cells/µL.
• Lower CD34-positive cell levels were observed in myelofibrosis patients achieving partial or complete response.
• A CD34-positive cell count ≥100/µL was independently predictive of higher mortality risk in myelofibrosis (HR=2.9).

Conclusions:

• Serial monitoring of circulating CD34-positive cells is valuable for evaluating disease progression in MPNs.
• CD34-positive cell levels provide prognostic information regarding overall survival in myelofibrosis.
• CD34-positive cell quantification can aid in risk stratification and management decisions for MPN patients.